Susceptibilities of Genital Mycoplasmas to the Newer Quinolones As Determined by the Agar Dilution Method GEORGE E

Total Page:16

File Type:pdf, Size:1020Kb

Susceptibilities of Genital Mycoplasmas to the Newer Quinolones As Determined by the Agar Dilution Method GEORGE E ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1989, p. 103-107 Vol. 33, No. 1 0066-4804/89/010103-05$02.00/0 Copyright © 1989, American Society for Microbiology Susceptibilities of Genital Mycoplasmas to the Newer Quinolones as Determined by the Agar Dilution Method GEORGE E. KENNY,'* THOMAS M. HOOTON,2 MARILYN C. ROBERTS,' FRANK D. CARTWRIGHT,' AND JEANNE HOYT' Department ofPathobiology SC-38, School ofPublic Health and Community Medicine,' and Department of Medicine, School of Medicine,2 University of Washington, Seattle, Washington 98195 Received 15 August 1988/Accepted 28 October 1988 The increasing resistance of genital mycoplasmas to tetracycline poses a problem because tetracycline is one of the few antimicrobial agents active against Mycoplasma hominis, Ureaplasma urealyticum, chlamydiae, gonococci, and other agents of genitourinary-tract disease. Since the quinolones are a promising group of antimicrobial agents, the susceptibilities ofM. hominis and U. urealyticum to the newer 6-fluoroquinolones were determined by the agar dilution method. Ciprofloxacin, difloxacin, and ofloxacin had good activity against M. hominis, with the MIC for 50% of isolates tested (MlC50) being 1 ,ug/ml. Fleroxacin, lomefloxacin, pefloxacin, and rosoxacin had MIC50s of 2 ,ug/ml. Enoxacin, norfloxacin, and amifloxacin had MIC50s of 8 to 16 ,ug/ml, and cinoxacin and nalidixic acid were inactive (M1C50, .256 ,ig/ml). Overall, the activities of 6-fluoroquino- lones for ureaplasmas were similar to those for M. hominis, with MICs being the same or twofold greater. The most active 6-fluoroquinolones against ureaplasmas were difloxacin, ofloxacin, and pefloxacin, with MICsos of 1 to 2 ,Ig/ml. Ciprofloxacin was unusual in that the MIC50 for M. hominis was 1 ,ug/ml, whereas the MIC50 for ureaplasmas was 8 ,Ig/ml. Since the MIC50s for the most active quinolones approximate achievable concentrations in blood and urine, quinolones have promise in treating mycoplasmal infections. The antibiotic susceptibility of the two most common MATERIALS AND METHODS genital mycoplasmas, Mycoplasma hominis and Ureaplas- Mycoplasmas. Two reference strains of M. hominis were ma urealyticum, is of increasing interest because of the obtained from the American Type Culture Collection recognition that these species are opportunistic pathogens (ATCC), 14027 and 23114T (the type strain). The reference when they extend beyond the genital tract, which they strains of U. urealyticum used included serovars 1 through 7, frequently colonize (34). Both species have been considered which were obtained from the American Type Culture to be generally susceptible to tetracyclines, but an increasing Collection as ATCC strains 27813, 27814, 27815, 27816, number of strains are being recovered which show high-level 27817, 27818, and 27819, respectively. Serovar 8, the type tetracycline resistance due to the presence of the tetracy- strain of the species (28), was obtained from M. Shepard as cline resistance element TetM (15, 21-23, 33). The situation strain 960 (cloned 8X). Serovar 9 (Vancouver) was obtained is further complicated by the fact that treatment of sexually from J. Robertson. The clinical isolates of each species (50 transmitted diseases has become more of a problem because for M. hominis and 50 for U. urealyticum) were obtained of the increase in gonococcal antimicrobial resistance. This from genitourinary specimens tested since 1971. All strains is due to the presence of plasmid-mediated high-level resis- and isolates were stored at -70°C. tance to tetracycline, plasmid-mediated 1-lactamase resis- Media. The broth medium used for growth of M. hominis tance, or chromosomally mediated antibiotic resistance to was soy peptone fresh yeast dialysate broth (12) supple- both penicillin and tetracycline in gonococci (16, 19). Since mented with 20% "agamma" horse serum, 0.001% phenol tetracycline was active against a broad range of sexually red, and 200 U of penicillin per ml. For U. urealyticum, the transmitted organisms (gonococci, Treponema pallidum, dialysate broth was supplemented with 5 mM urea, 10 mM chlamydiae, mycoplasmas, and ureaplasmas), its replace- MES [2-(N-morpholino)ethanesulfonic acid], 10% agamma ment will be difficult. Among the possible candidates for horse serum, 1 mM Na2SO3 (freshly prepared), 0.001% more general use are the quinolones, which are DNA gyrase phenol red, and 200 U of penicillin per ml. The final pH of inhibitors (39). Intense development has produced a large the broth medium was 7.0 to 7.3 for M. hominis and 6.0 to family of newer compounds, the 6-fluoroquinolones, which 6.3 for U. urealyticum. The agar medium employed for are active against a broad range of bacteria (9, 11, 17, 26, 30, antibiotic susceptibility testing for M. hominis was H agar 39). These agents have excellent pharmacokinetics and a (13). The H-agar base contained (per liter of water) 20 g of good safety profile. soy peptone (HySoy, Sheffield Chemical Co., Norwich, The purpose of our study was to determine the suscepti- N.Y.), 5 g of NaCl, 10 g of agarose, and 2 ml of a 1% phenol bilities of clinical isolates of U. urealyticum and M. hominis red solution. The pH was adjusted to 7.3. The complete to the newer quinolones by the agar dilution method. Several H-agar medium contained 70 ml of agar base, 10 ml of fresh quinolones were found to be active against both organisms at yeast dialysate (13), 20 ml of horse serum, and 200 ,ug of concentrations of 1 to 2 ,ug/ml, which are well within penicillin per ml. The final pH of the agar medium incubated attainable concentrations in serum and tissue. in air at 37°C was 7.3. For testing of susceptibilities of ureaplasmas, U agar (13) was used. U-agar base contained (per liter of water) 20 g of soy peptone, 5 g of NaCl, 4.25 g of MES (acid form), 12 g of agarose, and 2 ml of 1% phenol red. * Corresponding author. The pH was adjusted to 5.8 to 6.0. The complete medium 103 104 KENNY ET AL. ANTIMICROB. AGENTS CHEMOTHER. contained 70 ml of U-agar base, 10 ml of fresh yeast extract TABLE 1. Susceptibilities of M. hominis dialysate, 3 mM urea (0.3 ml of filter-sterilized 1 M urea per strains to quinolones 100 ml of agar medium), 200 U of penicillin per ml, and 20% MIC (p.g/ml) No. of strains whole horse serum. The final pH of U agar was 6.0 to 6.3 Quinolonea teted when incubated at 37°C in an atmosphere of 2.5% Co2 in air. 50%o 90o Range este Preparation of mycoplasmal inocula. Because mycoplas- Ciprofloxacin 1.0 1.0 0.5-1.0 34 mas do not show turbidity as evidence of growth in broth, Difloxacin 1.0 1.0 0.25-1.0 44 and because both M. hominis and U. urealyticum rapidly Ofloxacin 1.0 2.0 0.5-4.0 51 suicide after reaching peak growth, preparation of suitable Fleroxacin 2.0 2.0 0.5-4.0 43 inocula was much more difficult than with classical bacteria. Lomefloxacin 2.0 2.0 1.0-4.0 30 For M. hominis, stock frozen cultures (known to be viable at Pefloxacin 2.0 4.0 1.0-4.0 40 high plate counts) were thawed at room temperature, diluted Rosoxacin 2.0 4.0 0.5-4.0 43 Enoxacin 8.0 8.0 1.0-16.0 42 1:100 in fresh medium, and incubated for 24 h at 37°C. This Norfloxacin 8.0 8.0 4.0-8.0 42 tube was subcultured at 1:100 dilution into a new broth tube. Amifloxacin 16.0 32.0 1.0-32.0 52 The two tubes were incubated for an additional 24 h. If the Cinoxacin -128 .128 39 initial tube inoculated showed a haze or a slight alkaline pH Nalidixic acid -256 -256 36 shift after 24 h, the subculture was used for inocula for susceptibility testing. If no reaction was observed, samples a Listed in the order of descending activity (order is alphabetical for from both tubes were mixed and used as inocula. For compounds with the same activity). ureaplasmas, the frozen stock culture was inoculated into the ureaplasmal broth at 1:100 dilution. Eighteen hours later, 4, and 5, the number of colonies was counted. For U. a sample from this culture was serially diluted 1:100 and urealyticum, serial 10-fold dilutions were prepared and the 1:10,000 into two new tubes of medium. These three tubes 10-1, 10-2, and 10-3 dilutions were plated onto U agar. were incubated for 24 h, and the highest dilution which had Ureaplasmal colonies were stained on days 3 and 4 by just showed a color change from yellow to pink was used for spraying the plates with the calcium chloride-urea stain (13). the inoculum for the susceptibility test. For both Mycoplasma isolates and ureaplasmas, plates were Quinolones. The following quinolones (17, 39) were used: viewed with a stereoscopic dissecting microscope (cy- amifloxacin mesylate and rosoxacin (WIN 49375 and WIN cloptic; American Optical Corp., Buffalo, N.Y.) at a magni- 35213; Sterling-Winthrop Research Institute, Rensselaer, fication of x40. The MIC was the concentration of antimi- N.Y.), cinoxacin, (Lilly Research Laboratories, Indianapo- crobial agent (in micrograms per milliliter) which completely lis, Ind.), ciprofloxacin (Miles Laboratories, Inc., West prevented colony formation on spots known to contain 30 to Haven, Conn.), difloxacin (71-326-AL; Abbott Laboratories, 300 CFU as judged by the controls. The MIC50 was the Abbott Park, Ill.), enoxacin (Wamer-Lambert, Ann Arbor, concentration of antimicrobial agent which prevented colony Mich.), fleroxacin (AM 833; Hoffmann-LaRoche, Inc., Nut- formation of 50% of the strains tested, and the MIC90 was ley, N.J.), lomefloxacin (NY 198; G.
Recommended publications
  • Clinically Isolated Chlamydia Trachomatis Strains
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUIY 1988, p. 1080-1081 Vol. 32, No. 7 0066-4804/88/071080-02$02.00/0 Copyright © 1988, American Society for Microbiology In Vitro Activities of T-3262, NY-198, Fleroxacin (AM-833; RO 23-6240), and Other New Quinolone Agents against Clinically Isolated Chlamydia trachomatis Strains HIROSHI MAEDA,* AKIRA FUJII, KATSUHISA NAKATA, SOICHI ARAKAWA, AND SADAO KAMIDONO Department of Urology, School of Medicine, Kobe University, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe-city, Japan Received 9 December 1987/Accepted 29 March 1988 The in vitro activities of three newly developed quinolone drugs (T-3262, NY-198, and fleroxacin [AM-833; RO 23-6240]) against 10 strains of clinically isolated Chiamydia trachomatis were assessed and compared with those of other quinolones and minocycline. T-3262 (MIC for 90% of isolates tested, 0.1 ,ug/ml) was the most active of the quinolones. The NY-198 and fleroxacin MICs for 90% of isolates were 3.13 and 62.5 ,ug/ml, respectively. Recently, it has become well known that Chlamydia 1-ml sample of suspension was seeded into flat-bottomed trachomatis is an important human pathogen. It is respon- tubes with glass cover slips and incubated at 37°C in 5% CO2 sible not only for trachoma but also for sexually transmitted for 24 h. The monolayer was inoculated with 103 inclusion- infections, including lymphogranuloma venereum. In forming units of C. trachomatis. The tubes were centrifuged women, it causes cervicitis, endometritis, and salpingitis at 2,000 x g at 25°C for 45 min and left undisturbed at room asymptomatically (19), while in men it causes nongono- temperature for 2 h.
    [Show full text]
  • Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii
    ii Antibiotic Use Guidelines for Companion Animal Practice (2nd edition) iii Antibiotic Use Guidelines for Companion Animal Practice, 2nd edition Publisher: Companion Animal Group, Danish Veterinary Association, Peter Bangs Vej 30, 2000 Frederiksberg Authors of the guidelines: Lisbeth Rem Jessen (University of Copenhagen) Peter Damborg (University of Copenhagen) Anette Spohr (Evidensia Faxe Animal Hospital) Sandra Goericke-Pesch (University of Veterinary Medicine, Hannover) Rebecca Langhorn (University of Copenhagen) Geoffrey Houser (University of Copenhagen) Jakob Willesen (University of Copenhagen) Mette Schjærff (University of Copenhagen) Thomas Eriksen (University of Copenhagen) Tina Møller Sørensen (University of Copenhagen) Vibeke Frøkjær Jensen (DTU-VET) Flemming Obling (Greve) Luca Guardabassi (University of Copenhagen) Reproduction of extracts from these guidelines is only permitted in accordance with the agreement between the Ministry of Education and Copy-Dan. Danish copyright law restricts all other use without written permission of the publisher. Exception is granted for short excerpts for review purposes. iv Foreword The first edition of the Antibiotic Use Guidelines for Companion Animal Practice was published in autumn of 2012. The aim of the guidelines was to prevent increased antibiotic resistance. A questionnaire circulated to Danish veterinarians in 2015 (Jessen et al., DVT 10, 2016) indicated that the guidelines were well received, and particularly that active users had followed the recommendations. Despite a positive reception and the results of this survey, the actual quantity of antibiotics used is probably a better indicator of the effect of the first guidelines. Chapter two of these updated guidelines therefore details the pattern of developments in antibiotic use, as reported in DANMAP 2016 (www.danmap.org).
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • Original Article Fluoroquinolones Inhibit HCV by Targeting Its Helicase
    Antiviral Therapy 2012; 17:467–476 (doi: 10.3851/IMP1937) Original article Fluoroquinolones inhibit HCV by targeting its helicase Irfan A Khan1,2, Sammer Siddiqui1, Sadiq Rehmani1, Shahana U Kazmi2, Syed H Ali1,3* 1Department of Biological and Biomedical Sciences, Aga Khan University, Karachi, Pakistan 2Department of Microbiology, University of Karachi, Karachi, Pakistan 3Department of Microbiology, Dow University of Health Sciences, Karachi, Pakistan *Corresponding author e-mail: [email protected] Background: HCV has infected >170 million individuals of 12 different fluoroquinolones. Afterwards, Huh-7 and worldwide. Effective therapy against HCV is still lacking and Huh-8 cells were lysed and viral RNA was extracted. The there is a need to develop potent drugs against the virus. extracted RNA was reverse transcribed and quantified by In the present study, we have employed two culture models real-time quantitative PCR. Fluoroquinolones were also to test the activity of fluoroquinolone drugs against HCV: a tested on purified NS3 protein in a molecular-beacon- subgenomic replicon that is able to replicate independently based in vitro helicase assay. in the cell line Huh-8 and the Huh-7 cell culture model Results: To varying degrees, all of the tested fluoroqui- that employs cells transfected with synthetic HCV RNA to nolones effectively inhibited HCV replication in both produce the infectious HCV particles. Fluoroquinolones have Huh-7 and Huh-8 culture models. The inhibition of HCV also been shown to have inhibitory activity against certain NS3 helicase activity was also observed with all 12 of the viruses, possibly by targeting the viral helicase. To tease out fluoroquinolones.
    [Show full text]
  • DANMAP 2016 - Use of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Bacteria from Food Animals, Food and Humans in Denmark
    Downloaded from orbit.dtu.dk on: Oct 09, 2021 DANMAP 2016 - Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark Borck Høg, Birgitte; Korsgaard, Helle Bisgaard; Wolff Sönksen, Ute; Bager, Flemming; Bortolaia, Valeria; Ellis-Iversen, Johanne; Hendriksen, Rene S.; Borck Høg, Birgitte; Jensen, Lars Bogø; Korsgaard, Helle Bisgaard Total number of authors: 27 Publication date: 2017 Document Version Publisher's PDF, also known as Version of record Link back to DTU Orbit Citation (APA): Borck Høg, B. (Ed.), Korsgaard, H. B. (Ed.), Wolff Sönksen, U. (Ed.), Bager, F., Bortolaia, V., Ellis-Iversen, J., Hendriksen, R. S., Borck Høg, B., Jensen, L. B., Korsgaard, H. B., Pedersen, K., Dalby, T., Træholt Franck, K., Hammerum, A. M., Hasman, H., Hoffmann, S., Gaardbo Kuhn, K., Rhod Larsen, A., Larsen, J., ... Vorobieva, V. (2017). DANMAP 2016 - Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark. Statens Serum Institut, National Veterinary Institute, Technical University of Denmark National Food Institute, Technical University of Denmark. General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Users may download and print one copy of any publication from the public portal for the purpose of private study or research. You may not further distribute the material or use it for any profit-making activity or commercial gain You may freely distribute the URL identifying the publication in the public portal If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Drug
    Quantitative Safety & Epidemiology NVA237 / Glycopyrronium bromide Non-interventional Final Study Report NVA237A2401T Multinational, multi-database drug utilization study of inhaled NVA237 in Europe Author Document Status Final Date of final version 28 April 2016 of the study report EU PAS register ENCEPP/SDPP/4845 number Property of Novartis Confidential May not be used, divulged, published or otherwise disclosed without the consent of Novartis NIS Report Template Version 2.0 August-13-2014 Novartis Confidential Page 2 Non-interventional study report NVA237A/Seebri® Breezhaler®/CNVA237A2401T PASS information Title Multinational, multi-database drug utilization study of inhaled NVA237 in Europe –Final Study Report Version identifier of the Version 1.0 final study report Date of last version of 28 April 2016 the final study report EU PAS register number ENCEPP/SDPP/4845 Active substance Glycopyrronium bromide (R03BB06) Medicinal product Seebri®Breezhaler® / Tovanor®Breezhaler® / Enurev®Breezhaler® Product reference NVA237 Procedure number SeebriBreezhaler: EMEA/H/C/0002430 TovanorBreezhaler: EMEA/H/C/0002690 EnurevBreezhaler: EMEA/H/C0002691 Marketing authorization Novartis Europharm Ltd holder Frimley Business Park Camberley GU16 7SR United Kingdom Joint PASS No Research question and In the context of the NVA237 marketing authorization objectives application, the Committee for Medicinal Products for Human Use (CHMP) recommended conditions for marketing authorization and product information and suggested to conduct a post-authorization
    [Show full text]
  • Intracellular Penetration and Effects of Antibiotics On
    antibiotics Review Intracellular Penetration and Effects of Antibiotics on Staphylococcus aureus Inside Human Neutrophils: A Comprehensive Review Suzanne Bongers 1 , Pien Hellebrekers 1,2 , Luke P.H. Leenen 1, Leo Koenderman 2,3 and Falco Hietbrink 1,* 1 Department of Surgery, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands; [email protected] (S.B.); [email protected] (P.H.); [email protected] (L.P.H.L.) 2 Laboratory of Translational Immunology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands; [email protected] 3 Department of Pulmonology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands * Correspondence: [email protected] Received: 6 April 2019; Accepted: 2 May 2019; Published: 4 May 2019 Abstract: Neutrophils are important assets in defense against invading bacteria like staphylococci. However, (dysfunctioning) neutrophils can also serve as reservoir for pathogens that are able to survive inside the cellular environment. Staphylococcus aureus is a notorious facultative intracellular pathogen. Most vulnerable for neutrophil dysfunction and intracellular infection are immune-deficient patients or, as has recently been described, severely injured patients. These dysfunctional neutrophils can become hide-out spots or “Trojan horses” for S. aureus. This location offers protection to bacteria from most antibiotics and allows transportation of bacteria throughout the body inside moving neutrophils. When neutrophils die, these bacteria are released at different locations. In this review, we therefore focus on the capacity of several groups of antibiotics to enter human neutrophils, kill intracellular S. aureus and affect neutrophil function. We provide an overview of intracellular capacity of available antibiotics to aid in clinical decision making.
    [Show full text]
  • The Grohe Method and Quinolone Antibiotics
    The Grohe method and quinolone antibiotics Antibiotics are medicines that are used to treat bacterial for modern fluoroquinolones. The Grohe process and the infections. They contain active ingredients belonging to var- synthesis of ciprofloxacin sparked Bayer AG’s extensive ious substance classes, with modern fluoroquinolones one research on fluoroquinolones and the global competition of the most important and an indispensable part of both that produced additional potent antibiotics. human and veterinary medicine. It is largely thanks to Klaus Grohe – the “father of Bayer quinolones” – that this entirely In chemical terms, the antibiotics referred to for simplicity synthetic class of antibiotics now plays such a vital role for as quinolones are derived from 1,4-dihydro-4-oxo-3-quin- medical practitioners. From 1965 to 1997, Grohe worked oline carboxylic acid (1) substituted in position 1. as a chemist, carrying out basic research at Bayer AG’s Fluoroquinolones possess a fluorine atom in position 6. In main research laboratory (WHL) in Leverkusen. During this addition, ciprofloxacin (2) has a cyclopropyl group in posi- period, in 1975, he developed the Grohe process – a new tion 1 and also a piperazine group in position 7 (Figure A). multi-stage synthesis method for quinolones. It was this This substituent pattern plays a key role in its excellent achievement that first enabled him to synthesize active an- antibacterial efficacy. tibacterial substances such as ciprofloxacin – the prototype O 5 O 4 3 6 COOH F COOH 7 2 N N N 8 1 H N R (1) (2) Figure A: Basic structure of quinolone (1) (R = various substituents) and ciprofloxacin (2) Quinolones owe their antibacterial efficacy to their inhibition This unique mode of action also makes fluoroquinolones of essential bacterial enzymes – DNA gyrase (topoisomer- highly effective against a large number of pathogenic ase II) and topoisomerase IV.
    [Show full text]
  • Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active Or Latent Multidrug-Resistant Tuberculosis, Federated
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE HHS Public Access provided by Carolina Digital Repository Author manuscript Author ManuscriptAuthor Manuscript Author Pediatr Manuscript Author Infect Dis J. Author Manuscript Author manuscript; available in PMC 2017 April 01. Published in final edited form as: Pediatr Infect Dis J. 2016 April ; 35(4): 414–421. doi:10.1097/INF.0000000000001022. Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-Resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands Sundari R. Mase, MD, MPH1, John A. Jereb, MD1, Daniel Gonzalez, PharmD, PhD2,3,4, Fatma Martin, MD5, Charles L. Daley, MD6, Dorina Fred, MBBS7, Ann Loeffler, MD8, Lakshmy Menon, MPH1, Sapna Bamrah Morris, MD1, Richard Brostrom, MD1, Terence Chorba, MD1, and Charles A. Peloquin, PharmD, FCCP9 Sundari R. Mase: [email protected]; John A. Jereb: [email protected]; Daniel Gonzalez: [email protected]; Fatma Martin: [email protected]; Charles L. Daley: [email protected]; Dorina Fred: [email protected]; Ann Loeffler: [email protected]; Lakshmy Menon: [email protected]; Sapna Bamrah Morris: [email protected]; Richard Brostrom: [email protected]; Terence Chorba: [email protected]; Charles A. Peloquin: [email protected] 1Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA 2Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA 3Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA 4Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA 5North Bay Pediatrics, Vallejo, CA, USA 6National Jewish Health, Denver, CO, USA 7TB/Leprosy Program, Federated States of Micronesia (FSM) 8Francis J.
    [Show full text]
  • Simultaneous Determination of the Residues of Fourteen Quinolones
    Vol. 30, 2012, No. 1: 74–82 Czech J. Food Sci. Simultaneous Determination of the Residues of Fourteen Quinolones and Fluoroquinolones in Fish Samples using Liquid Chromatography with Photometric and Fluorescence Detection Florentina CAÑADA-CAÑADA, Anunciacion ESPINOSA-MAnsILLA, Ana JIMÉneZ GIRÓN and Arsenio MUÑOZ DE LA PeÑA Department of Analytical Chemistry, University of Extremadura, Badajoz, Spain Abstract Cañada-Cañada F., Espinosa-Mansilla A., Jiménez Girón A., Muñoz de la Peña A. (2012): Simul- taneous determination of the residues of fourteen quinolones and fluoroquinolones in fish samples using liquid chromatography with photometric and fluorescence detection. Czech J. Food Sci., 30: 74–82. A chromatographic method is described for assaying fourteen quinolones and fluoroquinolones (pipemidic acid, marbofloxacin, norfloxacin, ciprofloxacin, danofloxacin, lomefloxacin, enrofloxacin, sarafloxacin, difloxacin, oxolinic acid, nalidixic acid, flumequine, and pyromidic acid) in fish samples. The samples were extracted with m-phosphoric acid/acetonitrile mixture (75:25, v/v), purified, and preconcentrated on ENV + Isolute cartridges. The determina- tion was achieved by liquid chromatography using C18 analytical column. A mobile phase composed of mixtures of methanol-acetonitrile-10mM citrate buffer at pH 4.5, delivered under optimum gradient program, at a flow rate of 1.5 ml/min, allows accomplishing the chromatographic separation in 26 minutes. For the detection were used serial UV-visible diode-array at 280 nm and 254 nm and fluorescence detection at excitation wavelength/emission wavelength: 280/450, 280/495, and 280/405 nm. The detection and quantification limits were between 0.2–9.5 and 0.7–32 µg/kg, respectively. The procedure was applied to the analysis of spiked salmon samples at two different concentration levels (50 µg/k and 100 µg/kg).
    [Show full text]
  • Several Quinolones MICHAEL R
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1987, p. 1079-1084 Vol. 31, No. 7 0066-4804/87/071079-06$02.00/0 Copyright © 1987, American Society for Microbiology In Vitro Susceptibility of Coxiella burnetii to Antibiotics, Including Several Quinolones MICHAEL R. YEAMAN,1 LESTER A. MITSCHER,2 AND OSWALD G. BACA'* Department ofBiology, University of New Mexico, Albuquerque, New Mexico 87131,1 and Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas 660452 Received 16 March 1987/Accepted 13 April 1987 Antibiotic susceptibility testing of the rickettsial Q fever agent Coxiella burnetii was performed by using persistently infected L929 fibroblast cells. The efficacies of a variety of antibiotics with different metabolic targets were tested and compared. -The most effective antibiotics in bringing about the elimination of the parasite from infected cells included several quinolone compounds and rifampin. Of the'quinolone compounds tested, 'difloxacin (A-56619) was the most effective, followed by ciprofloxacin and oxolinic' acid. These three quinolones were apparently rickettsiacidal. After 48 h of exposure to micrQgram amounts of the compounds (ranging from 2 ,,g of difloxacin per ml to'5 jig of the other two antibiotics per ml), the number of intracellular parasites markedly declined; after' 10 days of treatment, very few intracellular rickettsiae were detected. Rifampin (1 ,Ig/ml) was also very effective in eliminating the parasites. Some of the 13 other antibiotics tested that were somewhat effective included chloramphemcol, doxycycline, and trimetloprim. The persistently infected L929 cells were found-to provide a convenient system for the relatively rapid determination of the susceptibility of C. burnetii to antibiotics.
    [Show full text]
  • Use of Antimicrobials in Veterinary Medicine and Mechanisms of Resistance Stefan Schwarz, Elisabeth Chaslus-Dancla
    Use of antimicrobials in veterinary medicine and mechanisms of resistance Stefan Schwarz, Elisabeth Chaslus-Dancla To cite this version: Stefan Schwarz, Elisabeth Chaslus-Dancla. Use of antimicrobials in veterinary medicine and mecha- nisms of resistance. Veterinary Research, BioMed Central, 2001, 32 (3-4), pp.201-225. 10.1051/ve- tres:2001120. hal-00902704 HAL Id: hal-00902704 https://hal.archives-ouvertes.fr/hal-00902704 Submitted on 1 Jan 2001 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Vet. Res. 32 (2001) 201–225 201 © INRA, EDP Sciences, 2001 Review article Use of antimicrobials in veterinary medicine and mechanisms of resistance Stefan SCHWARZa*, Elisabeth CHASLUS-DANCLAb a Institut für Tierzucht und Tierverhalten, Bundesforschungsanstalt für Landwirtschaft (FAL), Dörnbergstr. 25–27, 29223 Celle, Germany b Institut National de la Recherche Agronomique, Pathologie Aviaire et Parasitologie, 37380 Nouzilly, France (Received 18 December 2000; accepted 14 February 2001) Abstract – This review deals with the application of antimicrobial agents in veterinary medicine and food animal production and the possible consequences arising from the widespread and multi- purpose use of antimicrobials. The various mechanisms that bacteria have developed to escape the inhibitory effects of the antimicrobials most frequently used in the veterinary field are reported in detail.
    [Show full text]